首页> 外文期刊>JAMA: the Journal of the American Medical Association >Hematopoietic stem cell transplantation: a global perspective.
【24h】

Hematopoietic stem cell transplantation: a global perspective.

机译:造血干细胞移植:全球视野。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level. OBJECTIVES: To determine current use of HSCT to assess differences in its application and to explore associations of macroeconomic factors with transplant rates on a global level. DESIGN, SETTING, AND PATIENTS: Retrospective survey study of patients receiving allogeneic and autologous HSCTs for 2006 collected by 1327 centers in 71 participating countries of the Worldwide Network for Blood and Marrow Transplantation. The regional areas used herein are (1) the Americas (the corresponding World Health Organization regions are North and South America); (2) Asia (Southeast Asia and the Western Pacific Region, which includes Australia and New Zealand); (3) Europe (includes Turkey and Israel); and (4) the Eastern Mediterranean and Africa. MAIN OUTCOME MEASURES: Transplant rates (number of HSCTs per 10 million inhabitants) by indication, donor type, and country; description of main differences in HSCT use; and macroeconomic factors of reporting countries associated with HSCT rates. RESULTS: There were 50 417 first HSCTs; 21 516 allogeneic (43%) and 28 901 autologous (57%). The median HSCT rates varied between regions and countries from 48.5 (range, 2.5-505.4) in the Americas, 184 (range, 0.6-488.5) in Asia, 268.9 (range, 5.7-792.1) in Europe, and 47.7 (range, 2.8-95.3) in the Eastern Mediterranean and Africa. No HSCTs were performed in countries with less than 300,000 inhabitants, smaller than 960 km(2), or having less than US Dollars 680 gross national income per capita. Use of allogeneic or autologous HSCT, unrelated or family donors for allogeneic HSCT, and proportions of disease indications varied significantly between countries and regions. In linear regression analyses, government health care expenditures (r(2) = 77.33), HSCT team density (indicates the number of transplant teams per 1 million inhabitants; r(2) = 76.28), human development index (r(2) = 74.36), and gross national income per capita (r(2) = 74.04) showed the highest associations with HSCT rates. CONCLUSION: Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.
机译:背景:造血干细胞移植(HSCT)需要大量基础设施。在全球范围内对HSCT的使用及其相关因素知之甚少。目的:确定目前使用HSCT的方法,以评估其应用的差异,并在全球范围内探讨宏观经济因素与移植率之间的关系。设计,地点和患者:回顾性调查研究对象为2006年接受异体和自体HSCT的患者,这些患者来自全球血液和骨髓移植网络的71个参与国家的1327个中心。本文使用的区域区域是(1)美洲(世界卫生组织的相应区域是北美和南美); (2)亚洲(东南亚和西太平洋区域,其中包括澳大利亚和新西兰); (3)欧洲(包括土耳其和以色列); (4)东地中海和非洲。主要观察指标:按适应症,供体类型和国家分类的移植率(每1000万居民中HSCT的数量);描述HSCT使用的主要差异;报告国家与HSCT比率相关的宏观经济因素。结果:共有50 417例初次HSCT; 21 516同种异体(43%)和28 901同种异体(57%)。 HSCT的中位数率在地区和国家之间有所不同,美洲为48.5(范围为2.5-505.4),亚洲为184(范围为0.6-488.5),欧洲为268.9(范围为5.7-792.1),欧洲为47.7(范围为2.8) -95.3)在东地中海和非洲。在居民少于30万,小于960 km(2)或人均国民总收入少于680美元的国家中,没有进行过HSCT。异体HSCT的使用同种异体或自体HSCT,无关或家庭供体,以及疾病适应症的比例在国家和地区之间差异很大。在线性回归分析中,政府医疗保健支出(r(2)= 77.33),HSCT团队密度(指示每100万居民中的移植团队数量; r(2)= 76.28),人类发展指数(r(2)= 74.36)和人均国民总收入(r(2)= 74.04)显示与HSCT比率的最高关联。结论:造血干细胞移植在世界范围内被广泛用于适应症,但在国民总收入较高,政府医疗保健支出较高和团队密度较高的国家中最为常见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号